News
Company News: Curetis Completes Development of Unyvero Cartridge for Intra-Abdominal Infections; Presents at Key Investor and Scientific Conferences in Q1, 2017
– Highly multiplexed panel covers up to 112 diagnostic targets
– Third new panel developed within one year after IPO
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the completion of development of its fourth Application Cartridge.
The Unyvero IAI Cartridge is designed for the diagnosis of severe intra-abdominal infections and covers up to 74 bacteria, 13 fungi, 3 toxins and 22 resistance markers. The panel includes molecular markers for, among others, Clostridium difficile, Clostridium perfringens, Aeromonas spp. as well as for difficult-to-cultivate strains such as Prevotella spp. and comprises important antibiotic resistance markers such as Colistin resistance marker mcr-1, Fosfomycin resistance marker fosA3 and Nitroimidazol resistance markers nimA and nimB.
Initial verification and validation testing using clinical samples as well as blood cultures showed very promising interim data. The Unyvero IAI Cartridge will be made available for further routine clinical testing to several European hospitals in Q1/2017 for final clinical CE performance evaluation. Commercial roll-out in Europe is expected following the launch during the ECCMID 2017 conference in April. The IAI Cartridge aims to support clinicians in the fast and reliable diagnosis of various severe conditions, including peritonitis, acute abdomen and acute pancreatitis, and addresses a market of up to 1.9 million patients in hospitalized settings in Europe and the U.S. per year. Together with the Unyvero System, the IAI Cartridge can process a broad variety of clinical samples, including tissue, positively flagged blood cultures, ascites and gastric juice.
Complicated intra-abdominal infections are a common problem. In Germany, there are about 150,000 cases of severe intra-abdominal infections per year. In the U.S., appendicitis alone affects about 33,000 patients per year and is responsible for more than 1 million hospital days. Every fourth case of severe sepsis or septic shock can be attributed to intra-abdominal infections, and various independent studies show an overall mortality rate of 7.5%.
„We are excited about the fourth successfully completed new cartridge development program for Unyvero,” said Dr. Achim Plum CCO of Curetis. “The IAI Cartridge complements our Pneumonia, ITI and BCU cartridges and expands our portfolio of applications for severe infections in hospitalized patients. It will not only allow existing Unyvero customers to further broaden the use of their systems, but it will also attract new customer segments.”
“With now four highly multiplexed Unyvero Application Cartridges available on the Unyvero System, we have made it a truly versatile platform,” said Dr. Oliver Schacht, CEO of Curetis. “The IAI panel is a unique and highly differentiated syndromic testing panel and will be followed by new panels in the areas of urinary tract infections, cardiology-related infections, sepsis host response and expanded panels in respiratory diseases in the coming years.”
Curetis to Present at Key Investor and Scientific Conferences in the First Quarter 2017
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced its participation in several industry conferences in the first quarter of 2017. The respective presentations will be made available on the company’s website.
January:
J.P. Morgan 35th Annual Healthcare Conference 2017, January 9-13, 2017 – San Francisco, CA, USA: one-on-one meetings.
Society of Critical Care Medicine’s (SCCM) 46th Critical Care Congress, January 21-25, 2017 – Honolulu, Hawaii, USA: exhibition booth: 924.
Invest Securities BioMed Event, January 26, 2017 – Paris, France: company presentation and one-on-one meetings.
DeGroof Petercam Life Sciences Investor Day, January 31, 2017 – Brussels, Belgium: one-on-one meetings.
February:
3rd Annual Medtech & Money Healthcare Conference, February 7-8, 2017 – London, United Kingdom: company presentation and one-on-one meetings.
BIO CEO & Investor Conference, February 13-14, 2017 – New York, NY, USA: company presentation and one-on-one meetings.
RBC Healthcare Conference 2017, February 22-23, 2017 – New York, NY, USA: company presentation and one-on-one meetings.
March:
Microbiology and Infection 2017; 5th Joint Conference of the DGHM & VAAM
VAAM Annual Meeting 2017; 69th Annual Meeting of the DGHM, March 5-8, 2017 – Wuerzburg, Germany.
Sachs 10th European Life Science CEO Forum & Exhibition, March 6-7, 2017 – Basel, Switzerland: company presentation and one-on-one meetings.
BioCapital Europe 2017, March 15, 2017 – Amsterdam, The Netherlands: company presentation and one-on-one meetings.